Coming of age, Israel biotech sector gets ready for market


The sale of Israeli drugmaker NeuroDerm to Japanese pharma giant Mitsubishi Tanabe for $1.1 billion last month in the largest ever purchase of an Israeli healthcare company, has put the spotlight on Israel's biotech sector, where a number of other firms are gearing up for commercialization of their product. "This is a big deal," said Anya Eldan, vice president of the Israel Innovation Authority's Startup Division, about the NeuroDerm deal.



from Biotech News